Skip to main content

Nuvation Bio Inc.

corporate_fare Company Profile

Nuvation Bio Inc.

NUVB·NYSE·Life Sciences·CIK 0001811063

Nuvation Bio Inc. is a company that completed a business combination on February 10, 2021, through the merger of Panacea Acquisition Corp. and Legacy Nuvation Bio. Following this merger, Legacy Nuvation Bio became Nuvation Bio Operating Company Inc., and Panacea Acquisition Corp. changed its name to Nuvation Bio Inc. On February 11, 2021, the company's Class A common stock and warrants began trading on The New York Stock Exchange under the symbols "NUVB" and "NUVB.WS," respectively. On April 9, 2024, Nuvation Bio Inc. completed its acquisition of AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands. "Nuvation Bio" is a registered trademark of Nuvation Bio Inc. in the U.S. and other countries.

Nuvation Bio Inc. (NYSE:NUVB) is a publicly traded company in the Life Sciences sector. Wiseek monitors NUVB SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Nuvation Bio Secures Thermo Fisher for U.S. Manufacturing of Revenue-Generating Cancer Drug Ibtrozi
  • Nuvation Bio's IBTROZI Revenue Hits $18.5M, Clinical Data Shows 'Unprecedented Durability'
  • Nuvation Bio Reports First Net Income and Positive Operating Cash Flow Driven by Strong IBTROZI Sales and $58.7M Eisai Upfront Payment
  • Nuvation Bio Secures Japan Rights to Safusidenib from Daiichi Sankyo
  • Nuvation Bio Shares Plunge 26% on High Ibtrozi Discontinuation Rates

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$62.9M
Net Income
-$204.63M
Diluted EPS
-$0.60
Op. Cash Flow
-$173.43M
Free Cash Flow
-$181.43M
Operating Income
-$213.06M
Cash & Equivalents
$164.09M
Total Debt
$5.72M
Debt / Equity
0.02×
Net Margin
-325.3%
Shares Outstanding
337.84M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-085584
Browse all tickers starting with N →
$4.96 +0.04% today
52-week range · as of 2026-05-04 $1.57 – $9.75
Market cap
$1.72B
Volume
5.3M (1.1× avg)
3-mo avg 4.7M
Live data · 2026-06-14 05:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NUVB - Latest Insights

NUVB
May 13, 2026, 5:54 PM EDT
Source: Reuters
Importance Score:
7
Nuvation Bio Secures Thermo Fisher for U.S. Manufacturing of Revenue-Generating Cancer Drug Ibtrozi
Price at Filing: $4.78
Real-time Price: $4.96 info
Change: +$0.180 (+4%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article
NUVB
May 04, 2026, 4:10 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Nuvation Bio's IBTROZI Revenue Hits $18.5M, Clinical Data Shows 'Unprecedented Durability'
Price at Filing: $4.51
Real-time Price: $4.96 info
Change: +$0.450 (+10%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article
NUVB
May 04, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
9
Nuvation Bio Reports First Net Income and Positive Operating Cash Flow Driven by Strong IBTROZI Sales and $58.7M Eisai Upfront Payment
Price at Filing: $4.38
Real-time Price: $4.96 info
Change: +$0.580 (+13%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article
NUVB
Apr 01, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Nuvation Bio Secures Japan Rights to Safusidenib from Daiichi Sankyo
Price at Filing: $4.40
Real-time Price: $4.96 info
Change: +$0.560 (+13%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article
NUVB
Mar 03, 2026, 12:13 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Nuvation Bio Shares Plunge 26% on High Ibtrozi Discontinuation Rates
Price at Filing: $4.45
Real-time Price: $4.96 info
Change: +$0.515 (+12%) info
Market Cap: $1.718B info
Sentiment: Negative
View Wiseek Article
NUVB
Mar 02, 2026, 4:49 PM EST
Filing Type: 10-K
Importance Score:
8
Nuvation Bio Reports First Product Revenue, Strong Liquidity, and New European Partnership in Annual Report
Price at Filing: $5.68
Real-time Price: $4.96 info
Change: -$0.720 (-13%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article
NUVB
Mar 02, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
9
IBTROZI Sees Rapid Adoption, Nuvation Bio Inks Eisai Licensing Deal, Advances Pipeline
Price at Filing: $5.60
Real-time Price: $4.96 info
Change: -$0.6367 (-11%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article
NUVB
Jan 12, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
9
Nuvation Bio Secures Major Licensing Deal with Eisai for Taletrectinib, Reports Strong IBTROZI Launch & Path to Profitability
Price at Filing: $7.89
Real-time Price: $4.96 info
Change: -$2.93 (-37%) info
Market Cap: $1.718B info
Sentiment: Positive
View Wiseek Article